National Cancer Institute Multi-Ancestry Genome-Wide Association Study of Kidney Cancer (NCI-3)

The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer ("NCI-3") was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315 cases and 73,091 controls from 25 centers in North America, South America and Europe, genotyped using the Illumina Global Screening Array v2.0. SNP-level results from this GWAS were combined by meta-analysis with results from two earlier NCI European-ancestry GWAS (RCC; phs000351: 1,311 cases and 3,424 controls and phs001736: 2,417 cases and 4,391 controls), a NCI GWAS of African Americans (phs000863; 255 cases and 375 controls), GWAS conducted at other institutions [International Agency for Research on Cancer (scan 1: 2,438 cases and 5,071 controls; scan 2: 2,781 cases and 2,940 controls), The University of Texas MD Anderson Cancer Center (scan 1: 893 cases and 556 controls, scan 2: 1,241 cases and 1,712 controls) and the Institute for Cancer Research, UK (944 cases and 4,024 controls)] and GWAS analyses of data from three large biobanks (Biobank Japan: 523 cases and 86,306 controls; FinnGen: 2,095 cases and 304,956 controls; UK Biobank: 1,807 cases and 348,824 controls). Only individual-level data from NCI-3 and the two MD Anderson Cancer Center scans are included in this dbGaP submission. All study-specific and meta-analysis summary statistics are included.]]>
Meta-analysis of population-specific summary statistics from GWAS analyses of kidney cancer (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, NCI-USKCC, UK, FinnGen, Biobank Japan, UK Biobank).Meta-analysis of population-specific summary statistics from GWAS analyses of ccRCC (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, NCI-USKCC, FinnGen, UK Biobank).Meta-analysis of population-specific summary statistics from GWAS analyses of ccRCC (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, NCI-USKCC, FinnGen, UK Biobank).Meta-analysis of population-specific summary statistics from GWAS analyses of kidney cancer (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, NCI-USKCC, UK, FinnGen, Biobank Japan).Meta-analysis of population-specific summary statistics from GWAS analyses of ccRCC (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, NCI-USKCC, FinnGen).Meta-analysis of population-specific summary statistics from GWAS analyses of pRCC (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, NCI-USKCC, FinnGen).Meta-analysis of population-specific summary statistics from GWAS analyses of kidney cancer in EUR individuals (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, UK, FinnGen, UKB).Meta-analysis of population-specific summary statistics from GWAS analyses of ccRCC in EUR individuals (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, FinnGen, UKB).Meta-analysis of population-specific summary statistics from GWAS analyses of pRCC in EUR individuals (NCI-1, NCI-2, NCI-3, IARC, MDA, MDA-OA, UK, FinnGen, UKB).Meta-analysis of population-specific summary statistics from GWAS analyses of kidney cancer in AFR individuals (NCI-3, USKC-AA).Meta-analysis of population-specific summary statistics from GWAS analyses of ccRCC in AFR individuals (NCI-3, USKC-AA).Meta-analysis of population-specific summary statistics from GWAS analyses of pRCC in AFR individuals (NCI-3, USKC-AA).Meta-analysis of population-specific summary statistics from GWAS analyses of kidney cancer in EAS individuals (NCI-3, BBJ).Meta-analysis of population-specific summary statistics from GWAS analyses of kidney cancer in AMR individuals (NCI-3,LA1,LA2,Brazil).Meta-analysis of population-specific summary statistics from GWAS analyses of ccRCC in AMR individuals (NCI-3,LA1,LA2,Brazil).The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer (NCI-3) was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315 cases and 73,091 controls from 25 centers in North America, South America and Europe, genotyped using the Illumina Global Screening Array v2.0.The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer (NCI-3) was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315 cases and 73,091 controls from 25 centers in North America, South America and Europe, genotyped using the Illumina Global Screening Array v2.0.The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer (NCI-3) was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315 cases and 73,091 controls from 25 centers in North America, South America and Europe, genotyped using the Illumina Global Screening Array v2.0.The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer (NCI-3) was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315 cases and 73,091 controls from 25 centers in North America, South America and Europe, genotyped using the Illumina Global Screening Array v2.0.The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer (NCI-3) was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315 cases and 73,091 controls from 25 centers in North America, South America and Europe, genotyped using the Illumina Global Screening Array v2.0.The National Cancer Institute (NCI) multi-ancestral genome-wide association study (GWAS) of kidney cancer (NCI-3) was performed by NCI to further investigate common genetic variants associated with risk of kidney cancer and its two major subtypes across individuals of different ancestries (European, African, East Asian, Latin American). The NCI-3 GWAS includes 12,315 cases and 73,091 controls from 25 centers in North America, South America and Europe, genotyped using the Illumina Global Screening Array v2.0.The MD Anderson Cancer Center genome-wide association study (GWAS) of kidney cancer (MDA) was performed to investigate common genetic variants associated with risk of kidney cancer. The MDA GWAS includes 893 cases and 556 controls of European ancestry, genotyped using the Illumina 660W array. The MD Anderson Cancer Center OncoArray genome-wide association study (GWAS) of kidney cancer (MDA-OA) was performed to investigate common genetic variants associated with risk of kidney cancer. The MDA GWAS includes 1,241 cases and 1,712 controls of European ancestry, genotyped using the Illumina OncoArray 550K array.The IARC GWAS of kidney cancer were performed to investigate common genetic variants associated with risk of kidney cancer. The IARC GWAS include 5219 cases and 8011 controls of European ancestry, genotyped using the Illumina 317K, 550K, 610Q, OmniExpress and Omni5 arrays.The UK GWAS of kidney cancer was performed to investigate common genetic variants associated with risk of kidney cancer. The UK GWAS includes 944 cases and 5197 controls of European ancestry, genotyped using the Illumina OmniExpress and Hap 1.2M Duo arrays.The USKC-AA GWAS of kidney cancer was performed to investigate common genetic variants associated with risk of kidney cancer. The USKC-AA GWAS includes 255 cases and 375 controls of African American race/ethnicity, genotyped using the Illumina 1M Duo array.The UK Biobank GWAS of kidney cancer (UKB application number 86140) was performed to investigate common genetic variants associated with risk of kidney cancer. The UKB GWAS includes 1,807 cases and 348,824 controls of European ancestry, genotyped using the UK Biobank Axiom array. The FinnGen GWAS of kidney cancer was performed to investigate common genetic variants associated with risk of kidney cancer. The FinnGen GWAS includes 2,095 cases and 304,956 controls of European ancestry, genotyped using the FinnGen ThermoFisher Axiom custom array v2.The BBJ GWAS of kidney cancer was performed to investigate common genetic variants associated with risk of kidney cancer. The BBJ GWAS includes 523 cases and 86,306 controls of Japanese ancestry, genotyped using the  FinnGen ThermoFisher Axiom custom array v2.The NCI-1 GWAS of kidney cancer was performed to investigate common genetic variants associated with risk of kidney cancer. The NCI-1 GWAS includes 1,311 cases and 3,424 controls of European ancestry, genotyped using the Illumina 550, 610K, and 660W arrays.The NCI-2 GWAS of kidney cancer was performed to investigate common genetic variants associated with risk of kidney cancer. The NCI-2 GWAS includes 2,417 cases and 4,391 controls of European ancestry, genotyped using the Illumina OmniExpress and Omni 2.5 arrays.